
1. Pharmacogenomics J. 2016 Oct;16(5):439-45. doi: 10.1038/tpj.2016.44. Epub 2016
Jun 7.

Pharmacogenetic study of antipsychotic induced acute extrapyramidal symptoms in a
first episode psychosis cohort: role of dopamine, serotonin and glutamate
candidate genes.

Mas S(1)(2)(3), Gassó P(1)(2)(3), Lafuente A(1)(2)(3), Bioque M(2)(3)(4), Lobo
A(3)(5), Gonzàlez-Pinto A(3)(6), Olmeda MS(7), Corripio I(3)(8), Llerena A(9),
Cabrera B(2)(3)(4), Saiz-Ruiz J(3)(10), Bernardo M(2)(3)(4)(11); PEPs GROUP.

Collaborators: Mezquida G, Meseguer A, Bernardo EG, Parellada M, Alonso-Solís A, 
Grasa E, Hernandez M, Cengotitabengoa MM, Barcones F, Arbej J, Sanjuan J, Aguilar
EJ, Balbuena A, Mané A, Torrent C, Vieta E, Baeza I, Serna Ede L, Contreras F,
Albacete A, García-Portilla MP, Bobes J, Zabala Rabadán A, Segarra Echevarría R, 
Morales-Muñoz I, Rodriguez-Jimenez R, Butjosa A, Usall Rodie J, Sarró S,
Landín-Romero R, Ibañez Cuadrado A, Cuesta MJ, Balanzá-Martínez V.

Author information: 
(1)Department of Pathological Anatomy, Pharmacology and Microbiology, University 
of Barcelona, Barcelona, Spain.
(2)Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona,
Spain.
(3)Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM),Madrid,
Spain.
(4)Barcelona Clínic Schizophrenia Unit, Hospital Clínic de Barcelona, Barcelona, 
Spain.
(5)Department of Medicine and Psychiatry, Instituto de Investigación Sanitaria
Aragón (IIS Aragón), University of Zaragoza, Zaragoza, Spain.
(6)Department of Psychiatry, Hospital Universitario de Alava, University of the
Basque Country, Leioa, Spain.
(7)Department of Psychiatry, Hospital General Universitario Gregorio Marañón,
Madrid, Spain.
(8)Department of Psychiatry, Hospital de Sant Pau, Barcelona, Spain.
(9)CICAB Clinical Research Centre, Extremadura University Hospital and Medical
School Servicio Extremeño de Salud, Badajoz, Spain.
(10)Hospital Ramon y Cajal, Universidad de Alcala, IRYCIS, Madrid, Spain.
(11)Department of Psychiatry and Clinical Psychobiology, University of Barcelona,
Barcelona, Spain.

This study investigated whether the risk of presenting antipsychotic (AP)-induced
extrapyramidal symptoms (EPS) could be related to single-nucleotide polymorphisms
(SNPs) in a naturalistic cohort of first episode psychosis (FEP) patients. Two
hundred and two SNPs in 31 candidate genes (involved in dopamine, serotonin and
glutamate pathways) were analyzed in the present study. One hundred and thirteen 
FEP patients (43 presenting EPS and 70 non-presenting EPS) treated with
high-potency AP (amisulpride, paliperidone, risperidone and ziprasidone) were
included in the analysis. The statistical analysis was adjusted by age, gender,
AP dosage, AP combinations and concomitant treatments as covariates. Four SNPs in
different genes (DRD2, SLC18A2, HTR2A and GRIK3) contributed significantly to the
risk of EPS after correction for multiple testing (P<1 × 10(-4)). These findings 
support the involvement of dopamine, serotonin and glutamate pathways in
AP-induced EPS.

DOI: 10.1038/tpj.2016.44 
PMID: 27272046  [Indexed for MEDLINE]

